Monoclonal antibodies in chronic autoimmune inflammatory diseases;Les anticorps monoclonaux dans les maladies immunes inflammatoires chroniques

Medecine/Sciences

Volumn 25, Issue 12, 2009, Pages 1108-1112

  Semerano, Luca ^a   Boissier, Marie Christophe ^b  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74749106454     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925121108     Document Type: Review

References (15)

1. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984 ; 312 : 724-9.
2. Saklatvala J, Sarsfield SJ, Townsend Y. Pig interleukin 1. Purification of two immunoogically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med 1985 ; 162 : 1208-22.
3. Henderson B, Pettifer ER. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989 ; 75 : 306-10.
4. Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993 ; 36 : 1681-90.
5. Vital EM, Emery P. The development of targeted therapies in rheumatoid arthritis. J Autoimmunity 2008 ; 31 : 219-27.
6. Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008 ; 223 : 7-19.
7. Brennan F, Mc Innes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008 ; 118 : 3537-45.
8. Boissier MC, Assier E, Falgarone G, et al. Shifting the imbalance from Th1/ Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 2008 ; 75 : 373-5.
9. Scheinecker C, Redlich K, Smolen J. Cytokines as therapeutic targets: advances and limitations. Immunity 2008 ; 28 : 440-4.
10. Launois R, Payet S, Saidenberg-Kermanac'h N, et al. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008 ; 75 : 688-95.
11. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009 (sous presse).
12. Ranganathan P. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents. Curr Opin Mol Ther 2008 ; 10 : 562-7.
13. Delavallée L, Le Buanec H, Bessis N, et al. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 2008 ; 67 : 1332-8.
14. Gallois A, Mazzorana M, Vacher J, Jurdic P. Ostéo-immunologie : une vision globale et intégrée du tissu squelettique et du sytème immunitaire. Med Sci (Paris) 2009 ; 25 : 259-65.
15. Bensussan A, Bizzini B, Pouletty P, et al. Les kinoïdes : Une nouvelle génération de vaccins thérapeutiques. Med Sci (Paris) 2008 ; 24 : 306-13.